EP2046313A4 - The use of naphtoquinones in the treatment and control of diabetes, insulin resistance and hyperglycemia - Google Patents

The use of naphtoquinones in the treatment and control of diabetes, insulin resistance and hyperglycemia

Info

Publication number
EP2046313A4
EP2046313A4 EP07769053A EP07769053A EP2046313A4 EP 2046313 A4 EP2046313 A4 EP 2046313A4 EP 07769053 A EP07769053 A EP 07769053A EP 07769053 A EP07769053 A EP 07769053A EP 2046313 A4 EP2046313 A4 EP 2046313A4
Authority
EP
European Patent Office
Prior art keywords
naphtoquinones
hyperglycemia
diabetes
treatment
control
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP07769053A
Other languages
German (de)
French (fr)
Other versions
EP2046313A1 (en
Inventor
Mona Wilcke
Bo Svensson
Bjoern Walse
Tore Bengtsson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GLUCOX BIOTECH AB
Original Assignee
GLUCOX BIOTECH AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GLUCOX BIOTECH AB filed Critical GLUCOX BIOTECH AB
Publication of EP2046313A1 publication Critical patent/EP2046313A1/en
Publication of EP2046313A4 publication Critical patent/EP2046313A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A61K31/37—Coumarins, e.g. psoralen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
EP07769053A 2006-07-10 2007-07-06 The use of naphtoquinones in the treatment and control of diabetes, insulin resistance and hyperglycemia Withdrawn EP2046313A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE0601503 2006-07-10
SE0602611 2006-12-04
PCT/SE2007/050507 WO2008008033A1 (en) 2006-07-10 2007-07-06 The use of naphtoquinones in the treatment and control of diabetes, insulin resistance and hyperglycemia

Publications (2)

Publication Number Publication Date
EP2046313A1 EP2046313A1 (en) 2009-04-15
EP2046313A4 true EP2046313A4 (en) 2012-01-25

Family

ID=38923504

Family Applications (1)

Application Number Title Priority Date Filing Date
EP07769053A Withdrawn EP2046313A4 (en) 2006-07-10 2007-07-06 The use of naphtoquinones in the treatment and control of diabetes, insulin resistance and hyperglycemia

Country Status (2)

Country Link
EP (1) EP2046313A4 (en)
WO (1) WO2008008033A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2731849C (en) * 2008-07-25 2017-07-11 Emory University Use of 7,8-dihydroxyflavone and derivatives thereof as neuroprotectants and antidepressants
WO2012047628A2 (en) * 2010-09-27 2012-04-12 Emory University Methods of managing blood sugar levels and compositions related thereto
WO2014103862A1 (en) * 2012-12-26 2014-07-03 Nakajima Toshihiro Obesity preventive or therapeutic agent and rheumatism preventive or therapeutic agent
US20150344404A1 (en) * 2012-12-26 2015-12-03 The Kitasato Institue Pdk4 inhibitor and use thereof
KR101760565B1 (en) 2015-06-10 2017-07-31 포항공과대학교 산학협력단 Pharmaceutical composition for preventing or treating diabetic muscle atrophy comprising the activity inhibitor of tenc1
WO2018008984A1 (en) * 2016-07-05 2018-01-11 이화여자대학교 산학협력단 Pharmaceutical composition comprising epidithiodioxopiperazine compound or derivative thereof, or pharmaceutically acceptable salt thereof, for preventing or treating pulmonary hypertension
KR102032739B1 (en) * 2018-01-31 2019-10-16 한림대학교 산학협력단 Pharmaceutical composition for preventing and treating diabetic complications containing the novel chrysin derivative

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0638309A1 (en) * 1993-07-14 1995-02-15 ISTITUTO BIOCHIMICO ITALIANO GIOVANNI LORENZINI S.p.A. Substances inhibiting proteic adp ribosilation suitable to prevent the diabetes mellitus complications
EP0659883A2 (en) * 1993-11-24 1995-06-28 Ono Pharmaceutical Co., Ltd. Protein p140 and DNA encoding it
JPH1045575A (en) * 1996-07-31 1998-02-17 Kureha Chem Ind Co Ltd Hsp47 synthesis suppressor containing shikonin

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060070135A1 (en) * 1998-07-24 2006-03-30 Michel Tremblay Compositions and methods for inhibiting the enzymatic activity of PTP-1B
WO2002076939A2 (en) * 2001-02-05 2002-10-03 Exegenics Inc. Cysteine protease inhibitors
CA2463624A1 (en) * 2001-10-15 2003-04-24 National Research Council Of Canada Anti-glycation agents for preventing age-, diabetes-, and smoking-related complications
WO2003087399A1 (en) * 2002-04-17 2003-10-23 Glucox Ab Nad)p)h oxidase inhibitors for increased glucose uptake and treatment of type ii diabetes
KR20050036293A (en) * 2003-10-15 2005-04-20 동아제약주식회사 Cytosolic isocitrate dehydrogenase inhibitor containing naphthoquinones and their pharmaceutical compositions for preventing or treating obesity and hyperlipidemia
US7067659B2 (en) * 2004-04-23 2006-06-27 Duke University Reactive oxygen generating enzyme inhibitor with nitric oxide bioactivity and uses thereof
CN101027087A (en) * 2004-05-06 2007-08-29 罗伯特·F·霍夫曼 Use of targeted oxidative therapeutic formulation in treatment of diabetes and obesity

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0638309A1 (en) * 1993-07-14 1995-02-15 ISTITUTO BIOCHIMICO ITALIANO GIOVANNI LORENZINI S.p.A. Substances inhibiting proteic adp ribosilation suitable to prevent the diabetes mellitus complications
EP0659883A2 (en) * 1993-11-24 1995-06-28 Ono Pharmaceutical Co., Ltd. Protein p140 and DNA encoding it
JPH1045575A (en) * 1996-07-31 1998-02-17 Kureha Chem Ind Co Ltd Hsp47 synthesis suppressor containing shikonin

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI Week 199817, Derwent World Patents Index; AN 1998-189155, XP002665579 *
REIKO KAMEIA ET AL: "Shikonin Stimulates Glucose Uptake in 3T3-L1 Adipocytes via an Insulin-Independent Tyrosine Kinase Pathway", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ACADEMIC PRESS INC. ORLANDO, FL, US, vol. 292, no. 3, 5 April 2002 (2002-04-05), pages 642 - 651, XP008102880, ISSN: 0006-291X, [retrieved on 20020402], DOI: 10.1006/BBRC.2002.6714 *
See also references of WO2008008033A1 *

Also Published As

Publication number Publication date
EP2046313A1 (en) 2009-04-15
WO2008008033A1 (en) 2008-01-17

Similar Documents

Publication Publication Date Title
HRP20180667T1 (en) A klotho-beta agonist antibody for use in the treatment of diabetes mellitus or insulin resistance
EP2120959A4 (en) Methods and compositions for the treatment of insulin resistance, diabetes, and diabetes-associated dyslipidemia
IL246402A (en) Therapeutic agent for treating obesity, diabetes and diseases associated with impaired glucose tolerance
EP1758597A4 (en) Use of drug combinations for treating insulin resistance
GB0619860D0 (en) Treatment of insulin resistance and disorders associated therewith
IL211370A0 (en) Treatment for diabetes in patients with insufficient glycemic control desptie therapy with an oral or non-oral antidiabetic drug
IL237314A0 (en) Modified insulin polypeptides and their uses
IL215925A0 (en) Electrokinetically-altered fluid compositions and use thereof for treating insulin resistance and diabetes mellitus
WO2010049678A3 (en) Treatment of energy utilization diseases
EP2046313A4 (en) The use of naphtoquinones in the treatment and control of diabetes, insulin resistance and hyperglycemia
EP1799263A4 (en) Reducing er stress in the treatment of obesity and diabetes
EP1733749A4 (en) Syringe with connector, connector for syringe, and syringe
PL2419097T3 (en) Pharmaceutical composition comprising (1s)-1,5-anhydro-1-[5-(4-ethoxybenzyl)-2-methoxy-4-methylphenyl]-1-thio-d-glucitol and metformin and uses thereof in the treatment of diabetes
ZA201000990B (en) Herbal formulations for controlling blood glucose levels in patients with diabetes
EP2000164A4 (en) Self-destroying disposable syringe and self-destroying method thereof
EP1890708A4 (en) Glucose inducible insulin expression and methods of treating diabetes
EP2203169A4 (en) Glycemic control, diabetes treatment, and other treatments with acetyl cholinesterase inhibitors
ZA200900581B (en) Polypeptides and polynucleotides encoding same and use thereof in the treatment of medical conditions associated with ischemia
HK1076721A1 (en) A chinese traditional medical composition for treating diabetes and method for preparing the same
EP1872815A4 (en) Continuous subcutaneous insulin infusion therapy
WO2006007400A9 (en) Methods of diagnosing and treating obesity, diabetes and insulin resistance
HK1168283A1 (en) Sorcs1-like agent for use in the treatment of insulin resistance and diseases related thereto sorcs1
ZA201007061B (en) Pyridopyrazinones derivatives insulin secretion stimulators,methods for obtaining them and use thereof for the treatment of diabetes
ZA201008505B (en) Arylpyrazinone derivatives insulin secretion stimulators, methods for obtaining them and use thereof for the treatment of diabetes
IL211267A (en) Oxadiazole derivatives and medicaments and use thereof for the treatment of diabetes

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20090210

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR MK RS

A4 Supplementary search report drawn up and despatched

Effective date: 20111227

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 3/08 20060101ALN20111219BHEP

Ipc: A61P 3/06 20060101ALN20111219BHEP

Ipc: A61P 3/04 20060101ALN20111219BHEP

Ipc: A61P 3/10 20060101ALI20111219BHEP

Ipc: A61K 31/37 20060101ALI20111219BHEP

Ipc: A61K 31/122 20060101AFI20111219BHEP

DAX Request for extension of the european patent (deleted)
17Q First examination report despatched

Effective date: 20130425

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20160503